$137 Million is the total value of Birchview Capital, LP's 64 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLR | CONTINENTAL RESOURCES INC | $2,523,000 | +6.6% | 38,600 | 0.0% | 1.84% | +7.7% | |
| ALBO | ALBIREO PHARMA INC | $2,244,000 | -33.4% | 113,000 | 0.0% | 1.63% | -32.8% | |
| AXDX | ACCELERATE DIAGNOSTICS INC | $2,236,000 | -31.0% | 2,252,388 | 0.0% | 1.63% | -30.3% | |
| ALKS | ALKERMES PLC | $1,490,000 | +13.2% | 50,000 | 0.0% | 1.08% | +14.5% | |
| HROW | HARROW HEALTH INC | $1,310,000 | +6.7% | 180,000 | 0.0% | 0.95% | +7.8% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $1,215,000 | -38.8% | 269,332 | 0.0% | 0.88% | -38.1% | |
| CORT | CORCEPT THERAPEUTICS INC | $1,189,000 | +5.6% | 50,000 | 0.0% | 0.86% | +6.7% | |
| CYTK | CYTOKINETICS INC | $982,000 | +6.7% | 25,000 | 0.0% | 0.71% | +7.9% | |
| AVEO | AVEO PHARMACEUTICALS INC | $918,000 | +17.2% | 140,000 | 0.0% | 0.67% | +18.4% | |
| PXD | PIONEER NATURAL RESOURCES CO | $848,000 | -10.7% | 3,800 | 0.0% | 0.62% | -9.8% | |
| ETRN | EQUITRANS MIDSTREAM CORPORATIO | $846,000 | -24.7% | 133,050 | 0.0% | 0.62% | -23.9% | |
| DOCGO INC | $785,000 | -22.9% | 110,000 | 0.0% | 0.57% | -22.1% | ||
| SLNO | SOLENO THERAPEUTICS INC | $680,000 | -17.1% | 3,676,899 | 0.0% | 0.50% | -16.1% | |
| ARVN | ARVINAS INC | $631,000 | -37.5% | 15,000 | 0.0% | 0.46% | -36.9% | |
| CFRX | CONTRAFECT CORP | $614,000 | -15.9% | 200,000 | 0.0% | 0.45% | -15.0% | |
| TPTX | TURNING POINT THERAPEUTICS INC | $602,000 | +180.0% | 8,000 | 0.0% | 0.44% | +182.6% | |
| CGEM | CULLINAN MANAGEMENT INC | $578,000 | +22.5% | 45,114 | 0.0% | 0.42% | +23.5% | |
| APLS | APELLIS PHARMACEUTICALS INC | $543,000 | -11.0% | 12,000 | 0.0% | 0.40% | -10.0% | |
| CCXI | CHEMOCENTRYX INC | $496,000 | -1.0% | 20,000 | 0.0% | 0.36% | 0.0% | |
| NKTR | NEKTAR THERAPEUTICS | $486,000 | -29.6% | 128,000 | 0.0% | 0.35% | -28.8% | |
| IRTC | IRHYTHM TECHNOLOGIES INC | $432,000 | -31.4% | 4,000 | 0.0% | 0.31% | -30.8% | |
| FOLD | AMICUS THERAPEUTICS INC | $408,000 | +13.3% | 38,000 | 0.0% | 0.30% | +14.7% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $394,000 | -33.2% | 40,000 | 0.0% | 0.29% | -32.5% | |
| SILK | SILK ROAD MEDICAL INC | $364,000 | -11.9% | 10,000 | 0.0% | 0.26% | -10.8% | |
| XNCR | XENCOR INC | $337,000 | +2.7% | 12,300 | 0.0% | 0.24% | +3.8% | |
| PTGX | PROTAGONIST THERAPEUTICS INC | $301,000 | -66.6% | 38,000 | 0.0% | 0.22% | -66.2% | |
| KNSA | KINIKSA PHARMACEUTICALS LTD | $291,000 | -2.3% | 30,000 | 0.0% | 0.21% | -1.4% | |
| ZNTL | ZENTALIS PHARMACEUTICALS INC | $225,000 | -39.0% | 8,000 | 0.0% | 0.16% | -38.3% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $212,000 | -34.8% | 20,000 | 0.0% | 0.15% | -34.2% | |
| STOK | STOKE THERAPEUTICS INC | $198,000 | -37.3% | 15,000 | 0.0% | 0.14% | -36.6% | |
| GTHX | G1 THERAPEUTICS INC | $198,000 | -34.9% | 40,000 | 0.0% | 0.14% | -34.2% | |
| ISEE | IVERIC BIO INC | $144,000 | -42.9% | 15,000 | 0.0% | 0.10% | -42.0% | |
| IFRX | INFLARX NV | $102,000 | -20.3% | 70,000 | 0.0% | 0.07% | -19.6% | |
| CNCE | CONCERT PHARMACEUTICALS INC | $84,000 | +25.4% | 20,000 | 0.0% | 0.06% | +27.1% | |
| ANGN | ANGION BIOMEDICA CORP | $62,000 | -46.1% | 54,392 | 0.0% | 0.04% | -45.8% | |
| LSF | LAIRD SUPERFOOD INC | $53,000 | -47.5% | 28,000 | 0.0% | 0.04% | -46.6% | |
| YTEN | YIELD10 BIOSCIENCE INC | $42,000 | -57.6% | 18,750 | 0.0% | 0.03% | -56.3% | |
| SIEN | SIENTRA INC | $34,000 | -61.8% | 40,000 | 0.0% | 0.02% | -60.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.